|Ralph W. Moss, PhD, the whistleblower featured in my 3rd documentary, Second Opinion: Laetrile At Sloan-Kettering, publishes The Moss Reports blog. Ralph’s most recent post reports on how Goldman Sachs outright admitted that it would be bad for revenue if a cure for cancer was found.
“The potential to deliver ‘one shot cures’ is one of the most attractive aspects of gene therapy. However, such treatments offer a very different outlook with regard to recurring revenue versus chronic therapies. While this proposition [of one-shot cures] carries tremendous value for patients and society, it could represent a challenge for genome medicine developers looking for sustained cash flow.” ~ Ms. Salveen Richter, VP of Goldman’s Research Division
Read Ralph’s take on it here. Watch his video here. CNBC article here.